For MPAL with BCR::ABL1, treatment often involves tyrosine kinase inhibitors combined with ALL chemotherapy regimens, followed by allogeneic stem cell transplantation when possible.[17] Studies indicate that MPAL patients with the Ph + chromosome generally have a poor prognosis, with a median survival time of 8 months, compared to 139 months for those with normal karyotypes. The gene discussed is ABL1; the disease is mixed phenotype acute leukemia.